A $3.15bn deal follows a December 2024 option agreement.
ApexOnco Front Page
Recent articles
The groups spend big on Terns and Arcellx.
The group will take HRS-4642 into a Chinese phase 3 in first-line pancreatic cancer.
Varegacestat’s pivotal study reads out imminently.
Readout of the Preserve-003 trial in post-PD-(L)1 NSCLC is due in December.
ASH and SABCS approach.
New first-in-human trials include Kivu and Menarini projects acting on PKT7 and KIF18A.
The project has priority review, but deaths could raise eyebrows.
